Moreover, treatment with GNE-0723, a positive allosteric modulator of NR2A, reduces aberrant low-frequency oscillations and epileptiform discharges and improves cognitive functions in AD mouse models, suggesting that NR2A-subunit-containing NMDAR enhancers may have therapeutic benefits in brain disorders with network hypersynchrony and cognitive impairment [70]. Here, GRIN2A is linked to brain disorder.